Hepatology Submission Guide: Scope, Format & Tips

Week 1: Submission intake and editorial screen

The Hepatology Editorial Manager system verifies CONSORT/STROBE/PRISMA reporting-checklist completion, ethics statements, and trial registration ID. The handling Associate Editor then reads the cover letter and abstract to assess hepatology significance and mechanism-clinical bridge. About 60 to 70 percent of submissions are desk-rejected at this stage.

Week 2: Editorial discussion + AASLD family routing

Borderline papers are discussed across the Hepatology editorial team. Some receive transfer offers to Hepatology Communications (open access) or Liver Transplantation where reviewer reports can carry forward.

Weeks 3 to 4: Reviewer recruitment

For papers passing the editorial screen, 2 to 3 reviewers are recruited covering hepatology clinical context, mechanism rigor, and translational framing.

Weeks 5 to 8: External peer review

Reviewers evaluate hepatology significance, mechanism-clinical translation, methods rigor, and AASLD-readership relevance.

Weeks 8 to 10: Reviewer-report synthesis and decision

Handling editor integrates reports. Major-revision decisions specify the evidence gaps that must close before resubmission.

Hepatology is a fit when the paper is unmistakably liver-focused, methodologically strong, and easy for AASLD editors to connect to real hepatology questions. Submissions run through Editorial Manager, and the journal expects a tight original-research package rather than a broad exploratory manuscript.

How this page was created: we reviewed Hepatology author guidance, AASLD publication positioning, recent article patterns, and Manusights pre-submission review notes for liver-disease manuscripts.

We reviewed the 100 most recent Hepatology papers used when this guide was built, including DOI spot-checks such as 10.1097/HEP.0000000000001376, 10.1097/HEP.0000000000001565, and 10.1097/HEP.0000000000001549. We compared those accepted-paper patterns with recent manuscripts that were looking to submit to this journal through our Manusights work reviews.

Manusights internal analysis identifies a failure pattern: weak Hepatology submissions often have plausible liver-disease language, but the abstract, model choice, and figures do not prove that the mechanism is liver-specific enough for the AASLD flagship journal.

Evidence boundary: official author instructions tell you what to upload, but they do not tell you whether a hepatocyte-line result, mouse model, cohort size, or cover letter actually clears the liver-specific editorial screen. The submission decision should ask whether the liver biology would still feel central if the disease label were removed from the title.

Hepatology publishes research across the entire spectrum of liver biology and disease. If your work touches liver function, pathology, or treatment, it belongs here. The journal covers viral hepatitis (HBV, HCV, HDV), alcoholic liver disease, NAFLD/NASH, autoimmune liver diseases, liver cancer, transplantation, drug-induced liver injury, and basic hepatocyte biology.

• Research areas that fit:

• Hepatitis B and C virology and treatment

• NAFLD/NASH pathogenesis and therapeutics

• Liver fibrosis mechanisms and reversal

• Hepatocellular carcinoma biology and treatment

• Liver transplantation outcomes and immunology

• Drug hepatotoxicity mechanisms

• Liver regeneration and stem cell biology

• Portal hypertension and cirrhosis complications

• What doesn't belong: Generic inflammation studies that happen to use liver tissue. Broad metabolic papers where liver is just one organ examined. Gallbladder or bile duct research belongs in gastroenterology venues unless there's direct hepatocyte involvement.

The editors filter hard on liver specificity. Your introduction should demonstrate deep knowledge of liver-specific pathways, not general cell biology applied to hepatocytes. Studies using HepG2 cells need strong justification for why this model answers your specific liver question.

• Scope mismatch examples: Papers studying general autophagy that use liver as a convenient model. Broad studies of diabetes complications that mention liver involvement. Generic drug screening in hepatocyte cell lines without liver disease context.

Before you start writing, check recent issues. Notice how every accepted paper positions findings within established liver biology frameworks and connects directly to hepatology practice.

• Word limits are strict: 5,000 words maximum for original research articles, including everything except abstract, references, and figure legends. Brief communications cap at 1,500 words. Review articles can reach 8,000 words but require editorial pre-approval.

• Reference limits: Maximum 50 references for original articles. Brief communications get 25. Each reference needs complete information including page ranges and DOI when available.

• Abstract structure is mandatory: Use these exact headings: Background & Aims, Methods, Results, Conclusions. Keep under 250 words total. Don't use subheadings within each section.

• Figure specifications:

• Maximum 8 figures for original articles

• TIFF format preferred, minimum 300 DPI

• Color figures publish in color online, black/white in print unless you pay color fees

• Each figure needs a separate legend file, not embedded text

• Tables: Maximum 5 tables for original articles. Use standard Word table formatting. Don't submit tables as images.

• Supplementary material rules: Limited to essential data that supports main findings. Common supplements include additional patient characteristics, extended methods, or validation experiments. Don't dump borderline results here.

• Statistical requirements: Report exact p-values, not just p less than 0.05. Include confidence intervals. Specify statistical tests used. The journal requires power calculations for negative results in clinical studies.

• Human subjects: All human research needs IRB approval mentioned in Methods. Clinical trials require registration numbers. Patient consent must be documented.

• Animal studies: Include IACUC approval and specific strain information. Hepatology requires detailed housing conditions and fasting protocols for metabolic studies.

AASLD editors want to see liver expertise immediately. Don't start with generic statements about liver disease importance. Jump straight into what your specific findings add to hepatology knowledge.

• Opening paragraph template: "We report the specific finding in the specific liver disease/model that the specific advancement in understanding. This work addresses the specific gap in current hepatology knowledge and provides the specific clinical or mechanistic insight."

• Second paragraph: Explain why this finding matters to hepatologists specifically. Connect to established liver biology concepts. Reference recent Hepatology papers when relevant.

• Third paragraph: Brief methods overview focusing on liver-specific approaches. Mention if you used novel liver models, patient cohorts, or disease-specific endpoints.

• Fourth paragraph: Significance for the field. How does this change our understanding of liver disease mechanisms or treatment approaches?

• Common cover letter mistakes: Generic disease importance statements. Overselling preliminary findings. Failing to connect to established liver biology. Using phrases like "we believe" instead of stating findings directly.

• What signals expertise: Specific hepatology terminology used correctly. References to established liver disease frameworks. Understanding of current therapeutic challenges in hepatology.

The cover letter often determines whether your paper gets serious editorial attention or quick desk rejection. Cover letter examples specific to liver research can help you avoid common pitfalls.

• Generic inflammation studies: Papers that study general inflammatory pathways but happen to use liver tissue get rejected fast. Hepatology editors want liver-specific mechanisms, not general biology applied to hepatocytes. Your work needs to address why the liver responds differently from other organs or how liver-specific factors modulate general pathways.

• Single mouse strain without validation: Using only C57BL/6 mice limits translational relevance. Hepatology expects validation in multiple strains or models when claiming general mechanisms. The journal particularly scrutinizes diet-induced NASH models that don't recapitulate human disease features.

• Biomarker papers without mechanistic insight: Identifying new serum markers for liver disease isn't enough anymore. Editors want mechanistic understanding of why these markers change and how they connect to disease pathogenesis. Pure correlation studies get rejected unless they include substantial mechanistic validation.

• Overinterpreting hepatocyte cell line data: HepG2 and other immortalized hepatocyte lines have limited relevance to in vivo liver biology. Papers that draw broad conclusions about liver disease from cell line studies face immediate skepticism. You need primary hepatocytes or in vivo validation for major claims.

• Inadequate clinical context: Basic science papers that don't connect findings to human liver disease get filtered out during editorial screening. Even mechanistic studies need clear relevance to hepatology practice. Mention specific patient populations or therapeutic implications.

• Statistical power problems: Underpowered studies with n=3-4 per group don't meet Hepatology standards. Animal studies typically need n=8-10 minimum. Human studies require proper power calculations. Negative results without adequate power analysis get rejected.

• Scope creep into other organs: Papers that start with liver focus but drift into general metabolism or other organ systems lose editorial interest. Keep liver biology central throughout your story.

• Incomplete methods sections: Hepatology editors scrutinize liver-specific methodology closely. Fasting protocols for metabolic studies, hepatocyte isolation procedures, and liver histology scoring methods need complete details. Incomplete methods trigger immediate reviewer criticism.

• Weak translational bridge: Pure bench science without clinical relevance doesn't fit Hepatology's translational mission. Include discussion of how findings might impact patient care or suggest therapeutic targets. The journal wants research that advances both understanding and treatment of liver disease.

Before submitting to Hepatology, a Hepatology manuscript fit check identifies whether the package meets the editorial bar before you commit to the submission.

• Editorial screening: the editor-in-chief or associate editors first evaluate scope, quality, and likely impact. A large share of papers stop here if the fit is weak or the translational bridge is vague.

• Peer review assignment: if your paper passes screening, it moves to specialist reviewers with liver-disease expertise. Highly specialized topics can take longer simply because the reviewer pool is narrower.

• Reviewer response time: reviewer turnaround varies, and complicated translational packages can slow down because reviewers often look carefully at both the mechanistic and clinical sides of the paper.

• Editorial decision: Usually within one week of receiving all reviews. Most papers get "major revision" on first round. Straight acceptance is rare. Rejection after peer review happens when reviewers identify unfixable problems.

• Revision timeline: Authors get 3 months for major revisions, 6 weeks for minor revisions. Extension requests usually get approved if justified.

• Total timeline: expect a multi-stage process rather than a quick yes or no. Final acceptance often depends on how much additional support reviewers ask for.

The timeline moves faster when your methods are clear, results are straightforward, and clinical relevance is obvious. Check if your paper is ready before submitting to avoid delays from reviewer requests for additional experiments.

• Journal of Hepatology (European Association for Study of the Liver): Similar scope and quality to Hepatology. Impact factor 15.8. Slightly more European author representation. Faster publication timeline.

• Gastroenterology: Broader scope including liver, but harder to get liver papers accepted due to competition with GI tract research. JIF 22.7. Best for liver research with broader GI implications.

• Gut: Strong liver section with excellent clinical hepatology papers. JIF 24.5. More accessible than Gastroenterology for pure liver studies.

• American Journal of Transplantation: Perfect fit for liver transplantation research. JIF 8.8. Specialized audience but highly engaged readership.

• Journal of Clinical Investigation: For liver research with broad biomedical impact. JIF 15.9. Extremely selective but prestigious.

• Clinical Gastroenterology and Hepatology: Clinical focus with practice-relevant findings. JIF 12.6. Good alternative for translational liver research.

Consider journal scope carefully. Our journal selection guide helps match your liver research to the right venue based on methodology, clinical relevance, and target audience.

Before you upload, run your manuscript through a Hepatology submission readiness check to catch the issues editors filter for on first read.

For manuscripts targeting Hepatology, five patterns generate the most consistent desk rejections worth knowing before submission.

According to the American Association for the Study of Liver Diseases' flagship journal submission guidelines, each pattern below represents a documented desk-rejection trigger; per SciRev data and Clarivate JCR 2024 benchmarks, addressing these before submission meaningfully reduces early-rejection risk.

Hepatocyte line data without primary cell or in vivo validation

The Hepatology author guidelines require manuscripts to demonstrate liver-specific expertise and connect findings to hepatology practice, with specific attention to model validity for the claims being made. Manusights pre-submission pattern analysis shows many desk rejections involve manuscripts that draw broad conclusions about liver disease mechanisms from HepG2 or other immortalized hepatocyte line data without primary hepatocyte validation or in vivo evidence.

Editors specifically screen for manuscripts where the biological model is appropriate for the mechanistic claim, because cell line extrapolation to hepatic disease is among the most common reviewer objections at this journal tier.

Liver study without liver-specific mechanistic contribution

The same pattern analysis often finds many submissions study general biological pathways using hepatocytes or liver tissue as a convenient model without establishing that the mechanism is liver-specific, or without explaining how liver biology modifies the pathway relative to other organ systems. In practice, editors consistently desk-reject manuscripts where the hepatology angle is contextual rather than mechanistic, because the journal's scope requires that the liver-specific dimension be present in the data, not inferred from the disease population studied.

Biomarker paper without mechanistic connection to liver disease

A related pattern is that many submissions identify new serum or tissue markers for liver disease without demonstrating through mechanistic or functional data why those markers change and how they connect to hepatic disease pathogenesis. Editors consistently screen for manuscripts where the biomarker finding is supported by mechanistic interpretation, because pure correlation studies without biological validation have a consistently lower acceptance rate at Hepatology regardless of clinical cohort size.

Check biomarker paper without mechanistic connection to liver disease before submitting to Hepatology →

Sample size too small for the clinical liver claim made

A related pattern is that many submissions arrive with animal studies using fewer than 8-10 mice per group, or with clinical cohorts where the sample size is not justified relative to the claims being advanced about liver disease mechanisms or therapeutic relevance. In our analysis of submission difficulties at Hepatology, this pattern is most common when authors submit mechanistic liver research with sample sizes calibrated to a pilot-level threshold rather than to the evidence standards the journal applies for hepatic pathogenesis claims.

Check sample size too small for the clinical liver claim made before submitting to Hepatology →

Cover letter names the liver finding but omits the clinical payoff

A related pattern is that many submissions arrive with cover letters that describe the hepatological finding or the biological model without explaining what the results mean for hepatology practice, liver disease management, or therapeutic development. Editors explicitly consider whether the cover letter makes the translational case before routing the paper for peer review.

SciRev author-reported review times and Clarivate JCR 2024 bibliometric data provide additional benchmarks when planning your submission timeline.

Before submitting to Hepatology, a Hepatology submission readiness check identifies whether your translational framing, mechanistic evidence, and liver-specific relevance meet the editorial bar before you commit to the submission.

Or see example reports before you finalize.

Check cover letter names the liver finding but omits the clinical payoff before submitting to Hepatology →

• Hepatology submission process

• How to Avoid Desk Rejection at Hepatology

• Is Hepatology a Good Journal?

• Gut vs Hepatology